Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement
| Autor: | G.J. Lankhorst, Johannes B. J. Bussmann, H L D Horemans, Machiel J. Zwarts, D.F. Stegeman, F. Nollet, Anita Beelen, Gea Drost, M. de Visser |
|---|---|
| Přispěvatelé: | Rehabilitation medicine, Amsterdam Movement Sciences, Neurology, Rehabilitation Medicine, Faculteit der Geneeskunde |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Paper Weakness medicine.medical_specialty Placebo-controlled study Neuromuscular transmission Placebo Severity of Illness Index SDG 3 - Good Health and Well-being Double-Blind Method medicine Humans Exercise Tolerance Muscle fatigue business.industry Middle Aged Neuromuscular development and genetic disorders [UMCN 3.1] Psychiatry and Mental health Postpoliomyelitis Syndrome Treatment Outcome Pyridostigmine Muscle Fatigue Physical therapy Female Surgery Pyridostigmine Bromide Cholinesterase Inhibitors Neurology (clinical) medicine.symptom business Psychomotor Performance Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Neurology, Neurosurgery, and Psychiatry, 74, 12, pp. 1655-61 Journal of Neurology, Neurosurgery, and Psychiatry, 74, 1655-61 Journal of neurology, neurosurgery, and psychiatry, 74(12), 1655-1661. BMJ Publishing Group Journal of Neurology, Neurosurgery and Psychiatry, 74(12), 1655-1661. BMJ Publishing Group Journal of Neurology, Neurosurgery and Psychiatry, 74, 1655-1661. BMJ Publishing Group |
| ISSN: | 0022-3050 |
| DOI: | 10.1136/jnnp.74.12.1655 |
| Popis: | Item does not contain fulltext OBJECTIVES: To investigate the effect of pyridostigmine on fatigue, physical performance, and muscle function in subjects with postpoliomyelitis syndrome. METHODS: 67 subjects with increased fatigue and new weakness in one quadriceps muscle showing neuromuscular transmission defects, were included in a randomised, double blind, placebo controlled trial of 60 mg pyridostigmine four times a day for 14 weeks. Primary outcome was fatigue (on the "energy" category of the Nottingham health profile). Secondary outcomes included two minute walking distance and quadriceps strength and jitter. Motor unit size of the quadriceps was studied as a potential effect modifier. The primary data analysis compared the changes from baseline in the outcomes in the last week of treatment between groups. RESULTS: 31 subjects treated with pyridostigmine and 31 subjects treated with placebo completed the trial. No significant effect of pyridostigmine was found on fatigue. The walking distance improved more in the pyridostigmine group than in the placebo group (by 7.2 m (6.0%); p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|